A Study of Raltegravir in a Diverse Cohort of HIV-Infected Patients (0518-055)

• Status: Completed
• Trial end date: 2011-02-01
• Target enrollment: 0
• Participant gender: All

Summary

A study to test the safety and effect of twice daily raltegravir in a diverse cohort of patients currently infected with human immunodeficiency virus (HIV), where at least 50% are African American and at least 25% are female, either having received antiretroviral drugs before or not.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Raltegravir Potassium

Criteria

Inclusion Criteria:

• Patient is HIV positive

• Patient agrees to use (or have their partner use) birth control as defined by the study doctor

Exclusion Criteria:

• If female, pregnant or breastfeeding

• Patient has used an investigational agent in the last 30 days

• Patient has acute hepatitis

• Patient has received MK0518 (raltegravir) before

• Patient has used another experimental HIV-integrase inhibitor